Ozempic vs Retatrutide: Long-Term Durability of Response

Current status: Retatrutide is investigational and not FDA-approved. It is not available for public use; federal law does not permit it to be compounded, and HealthRX does not offer it.

Evidence directly relevant to published and registered clinical research

Cross-trial outcome estimates come from different populations and protocols. They do not substitute for head-to-head evidence or an FDA benefit-risk review.

Published phase 2 evidence

The peer-reviewed phase 2 obesity trial randomized 338 adults and reported body-weight and safety outcomes over 48 weeks. Gastrointestinal adverse events were the most frequently reported, and increases in heart rate were observed. The study evaluated protocol-defined doses in research participants; it did not create an approved dose or public treatment protocol [1].

Registered and sponsor-reported phase 3 evidence

ClinicalTrials.gov lists TRIUMPH-1 as a completed phase 3 study with 2,335 participants [2]. In 2026, Lilly announced topline results from several phase 3 trials. Those sponsor reports add evidence, but they are not substitutes for complete peer-reviewed publications or FDA review [4].

Current regulatory record

FDA states that retatrutide is not a component of an approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law [3].